<DOC>
	<DOCNO>NCT01494727</DOCNO>
	<brief_summary>The objective study : - To compare safety profile CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg single oral administration healthy male volunteer - To compare pharmacokinetic profile CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg single oral administration healthy male volunteer</brief_summary>
	<brief_title>Phase I Study Compare Safety , Pharmacokinetic Profiles CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg</brief_title>
	<detailed_description />
	<mesh_term>Amlodipine , Valsartan Drug Combination</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>Male volunteer age 20 45 year old Body Mass Index ( BMI ) range 19 27 kg/m2 History allergy sensitivity drug , include amlodipine valsartan History clinically significant hepatic , renal , gastrointestinal , neurology , pulmonary , endocrine , musculoskeletal , hematologic , oncologic , psychiatric , especially cardiovascular disease History surgery except gastrointestinal disease might significantly change absorption medicine Hypotension ( Systolic Blood Pressure ( SBP ) ≤ 100 mmHg Diastolic Blood Pressure ( DBP ) ≤ 65 mmHg ) Hypertension ( SBP ≥ 150 mmHg DBP ≥ 95 mmHg ) Clinical laboratory test value outside accept normal range Aspartate Transaminase ( AST ) Alanine Transaminase ( ALT ) &gt; 1.25 time normal range Total bilirubin &gt; 1.25 time normal range Positive Hepatitis B Virus surface Antigen ( HBsAg ) , Hepatitis C Virus Antibody ( HCVAb ) Human Immunodeficiency Virus Antibody ( HIVAb )</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>